Luvo Health Review 2026: '$45 a Week' Billed Annually, and a Compounding Pathway the FDA Is Closing

Luvo Health (luvohealth.com) is a cash-pay telehealth platform selling three things: longevity injectables and sprays (NAD+, sermorelin, B12/MIC), GLP-1 weight loss in both compounded and brand form, and a "microdosing" GLP-1 programme, plus a skincare line. A clinician reviews your intake and prescribes where appropriate, and medication ships from partner pharmacies. It is US-only, cash-pay, and very new—the affiliate programme launched on July 14, 2026, two weeks before we looked at it. We priced it and read its policies on July 29, 2026. This review contains affiliate links; the assessment is our own. It is informational only and not medical advice, and there are three things a prospective buyer should understand before the marketing.

The Weekly Price Is an Annual Bill

Luvo advertises in weekly numbers. Every one of them is followed by two words that change the meaning entirely. From its own service pages, checked July 29, 2026:

Weight loss — "starting at $45 per week · billed annually", which is roughly $2,340 charged as one payment
Microdosing — "starting at $42 per week · billed annually", roughly $2,184 for the year
Longevity (NAD+, sermorelin, B12/MIC) — "starting at $25 per week · billed annually", roughly $1,300 for the year
Skincare — $99 per month per formula, the only line billed monthly
Programmes include clinical evaluation, a clinician-guided plan, prescription medication where appropriate, provider messaging, dose adjustments and pharmacy fulfilment

"$45 per week" and "$2,340 today" are the same offer described two different ways, and only one of them tells you what leaves your account. Before you enter card details, work out the annual figure and decide whether you would pay it as a lump sum—because that is the decision you are actually making. Luvo does say there is "no commitment until clinician review", which is a genuine protection: you are not charged before a clinician has looked at your intake.

What "Cancel Anytime" Actually Buys You

Luvo's service pages say "Cancel anytime." Its cancellation and refund policy is more specific, and the detail matters when you have prepaid a year. You may cancel at any time for any reason, but the request must arrive at least 72 hours before your next billing date. Where a bundled plan is refunded, the policy states that "refunds will be calculated on a prorated basis using the standard, non-bundled monthly retail price in effect at the time of purchase." Read that carefully, because it is the most consequential sentence on the site. You buy an annual bundle at a discounted effective rate. If you cancel partway through, the months you used are charged back at the standard non-bundled monthly price—the higher, undiscounted one—and you are refunded what remains. The further into the year you cancel, the more of your prepayment is absorbed at the higher rate. This is a common structure and it is disclosed rather than hidden, but it means the annual discount is only real if you complete the year. Two further limits: prescription medication already ordered cannot be refunded, which the policy attributes to federal law and which is standard across the industry, and clinical services "are non-refundable once rendered, regardless of medication fulfillment status." So a consultation you paid for and a shipment already dispatched both stay paid for.

If you want to try Luvo without the annual exposure, ask support whether a monthly option exists before signing up—the skincare line is billed monthly, so the billing system supports it. And diarise the 72-hour notice window relative to your renewal date rather than relying on remembering it.

The Compounded GLP-1 Problem Is Bigger Than This Company

Luvo sells compounded semaglutide injection, compounded semaglutide tablets and compounded tirzepatide injection, plus microdosing versions of all three. It also sells brand Ozempic® and Zepbound®. That distinction is the single most important thing on this page, because the two categories are in completely different regulatory positions. Compounded GLP-1s were widely available because the branded drugs were in shortage, which opened a legal pathway for compounding. Those shortages are over: the FDA declared the tirzepatide shortage resolved in October 2024 and the semaglutide shortage resolved in February 2025. Then, on April 30, 2026, the FDA proposed to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound them from bulk drug substances. The comment period closed on June 29, 2026. The practical position today is that semaglutide and tirzepatide appear on neither the 503B bulks list nor the drug shortage list. Outsourcing facilities may not compound from bulk substances unless a substance is on the bulks list or the drug is on the shortage list at the time of compounding, distribution and dispensing. The legal ground that supported mass-market compounded GLP-1s has largely gone. Brand Ozempic® and Zepbound® are unaffected. They are FDA-approved products, and a platform that can route you to them is offering something materially different from a compounded vial.

If you sign up here for weight loss, ask one question before paying: will I be dispensed a compounded product or an FDA-approved brand one, and from which pharmacy? Compounded semaglutide and tirzepatide are not FDA-approved finished products—Luvo states this itself—and their supply pathway is being narrowed as we write. Committing a year in advance to a compounded medication whose availability depends on an unsettled federal position is the specific risk to avoid. If you want certainty, ask for the brand pathway and price it accordingly.

"Microdosing" Is a Marketing Term, Not a Protocol

Luvo sells a distinct microdosing programme—microdosing tirzepatide injection, microdosing semaglutide injection and microdosing semaglutide tablets—at $42 per week billed annually, which is only marginally cheaper than the full weight-loss programme at $45. There is no established clinical evidence base for GLP-1 microdosing as a defined therapy. The approved products have dose-escalation schedules studied in trials, with efficacy and safety data attached to specific doses. Taking deliberately sub-therapeutic amounts on an ongoing basis is not one of those studied regimens; it is a commercial construct that has grown up around compounded supply, where a vial can be divided in ways a manufactured pen cannot. That does not make it harmful in itself, and some clinicians do use low doses deliberately for tolerability. But you should know that you are buying something outside the evidence base, at a price close to the full programme, on an annual commitment.

If the appeal of microdosing is fewer side effects, that is a conversation to have with a prescriber about slower titration of a standard product—not a separate paid programme. If the appeal is lower cost, note that Luvo prices it within $3 a week of the full weight-loss plan, which undercuts the rationale.

What You Cannot Find Out Before Paying

Luvo is two weeks old as an affiliate programme and its public footprint is correspondingly thin. We searched for an independent review record—Trustpilot, BBB, consumer complaint boards, news coverage—and found nothing substantive for this brand. That is not evidence of anything bad. It is an absence of evidence, and for a service taking $1,300 to $2,340 upfront and dispensing prescription medication, the absence is itself the finding. Things we could not establish from the site: which states it operates in, the names or credentials of the prescribing clinicians beyond "licensed healthcare provider," and which pharmacies fulfil orders beyond a generic reference to a "licensed pharmacy partner." Its FAQ does not address annual billing, and directs unanswered questions to a support email. To its credit, the site does publish a cancellation and refund policy, a privacy policy and terms and conditions, it states plainly that compounded medications are not FDA-approved, and it does not charge before clinician review. Those are real, and several better-known platforms we have reviewed do worse on the disclosure front.

Before paying an annual fee, get four things in writing from support: that Luvo is licensed to treat patients in your state, whether your prescription will be compounded or brand, which pharmacy will fulfil it, and a worked example of what your refund would be if you cancelled at month three. If any of those cannot be answered plainly, that is your answer.

Safety, Eligibility and Who Should Not Use This

GLP-1 receptor agonists are effective medicines with real contraindications, and the same rules apply whether the product is branded or compounded. They are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. They should not be used in pregnancy or while trying to conceive, and they can reduce the effectiveness of oral contraceptives. Pancreatitis, gallbladder disease, severe gastrointestinal disease including gastroparesis, and diabetic retinopathy all require specific medical assessment first. The common side effects—nausea, vomiting, diarrhoea, constipation—are frequent enough that tolerability, not efficacy, is the usual reason people stop. The longevity products carry a different problem: limited evidence rather than defined risk. NAD+ in oral, spray and injectable form, and sermorelin as a growth-hormone secretagogue, have thin clinical evidence for the anti-ageing benefits they are marketed on. Compounded products of any kind are not FDA-approved finished products, which means the specific formulation you receive has not been reviewed for safety, efficacy or manufacturing quality the way an approved drug has.

Do not start a GLP-1 without a clinician who knows your full history—these are not lifestyle purchases. Do not use them if you are pregnant, breastfeeding or trying to conceive, or if you have a personal or family history of medullary thyroid carcinoma or MEN 2. Tell your prescriber about pancreatitis, gallbladder disease, gastroparesis, diabetic retinopathy, and any other medication you take. If you develop severe or persistent abdominal pain, seek medical care immediately—that is the presentation of pancreatitis. Consult your own physician before starting or changing any treatment described here.

How It Compares

Against the telehealth platforms we have reviewed, Luvo's distinguishing features are its annual billing and its newness. Prices as published by each operator, checked July 29, 2026:

Luvo Health — weight loss from $45/week and longevity from $25/week, both billed annually ($2,340 and $1,300 respectively) · compounded and brand GLP-1 pathways · no clinician charge before review · no independent review record; states, prescribers and pharmacies undisclosed
Live Vital (our review) — physician-supervised peptide telehealth from $66/month, billed monthly · a named medical lead · same category, far lower commitment to try
Feel30 (our review) — TRT with at-home nurse phlebotomy, $99-$129 initial panel and $199-$235/month · labs included, monthly billing
Talkiatry (our review: 7.3/10) — the contrast case for what disclosure looks like: named clinical model, in-network insurance billing, no upfront annual commitment
Brand Ozempic® or Zepbound® through insurance or a conventional prescriber — the FDA-approved pathway, unaffected by the compounding position, and worth pricing against any cash-pay programme if you have coverage

The comparison that matters most for a GLP-1 buyer is not platform against platform—it is compounded against brand. If you have insurance coverage for Zepbound or Ozempic, or can access them through a conventional prescriber, that route gives you an FDA-approved product with a stable supply position. Cash-pay compounded programmes made sense when the branded drugs were in shortage. That shortage ended in 2025.

Honest Pros and Cons

What we would tell a friend, in both directions:

Pro — offers brand Ozempic® and Zepbound® alongside compounded options, so an FDA-approved pathway exists
Pro — no charge until a clinician has reviewed your intake, which is a real protection against paying for an ineligible signup
Pro — publishes a cancellation and refund policy, terms and conditions and a privacy policy, and states plainly that compounded medications are not FDA-approved
Pro — refunds on bundled plans are prorated rather than forfeited entirely
Pro — one platform covering weight loss, longevity injectables and skincare, with clinician messaging and dose adjustments included
Con — headline pricing is weekly but billing is annual: $2,340 upfront for weight loss, $1,300 for longevity
Con — prorated refunds are calculated at the standard non-bundled monthly rate, so cancelling mid-year erodes the discount you prepaid for
Con — the brand is roughly two weeks old with no independent review record we could find anywhere
Con — states served, prescriber names and fulfilling pharmacies are all undisclosed
Con — compounded semaglutide and tirzepatide now sit on neither the 503B bulks list nor the shortage list, after the FDA's April 30, 2026 proposal
Con — the microdosing programme has no established evidence base and costs within $3 a week of the full programme
Con — NAD+ and sermorelin are marketed on anti-ageing benefits with limited clinical support

Who Should Pick It—and Who Should Look Elsewhere

Luvo could suit someone who has already decided on a year of cash-pay treatment, wants weight loss and longevity products managed on one platform, has confirmed with support that they will receive a brand rather than compounded GLP-1, and is comfortable being an early customer of a business with no track record. The no-charge-until-review policy makes the initial step low-risk, and the disclosure quality is better than several larger competitors. Look elsewhere if you want to try before committing—an annual bill is the wrong structure for finding out whether a GLP-1 suits you, and monthly-billed competitors exist. Look elsewhere if you want to know who is treating you, since prescribers and pharmacies are unnamed. Look elsewhere if you have insurance coverage for Zepbound or Ozempic, where the approved product through a conventional route is both safer ground and often cheaper. And look elsewhere if the compounded pathway is what attracted you, because that is precisely the pathway federal regulators are closing.

Common Questions

Quick answers to what buyers actually search:

How much does Luvo Health cost? — Weight loss from $45 per week, microdosing from $42 per week and longevity from $25 per week, all billed annually — roughly $2,340, $2,184 and $1,300 respectively. Skincare is $99 per month. Checked July 29, 2026.
Is Luvo Health legit? — It is a real, operating telehealth platform that publishes terms, a privacy policy and a refund policy, and does not charge before clinician review. It is also about two weeks old with no independent review record, and it does not disclose its states, prescribers or pharmacies.
Can I cancel Luvo Health? — Yes, at any time, with at least 72 hours' notice before your next billing date. Bundled plans are refunded prorated, but calculated at the standard non-bundled monthly rate, so cancelling mid-year gives back less than a simple pro rata split would.
Is compounded semaglutide still legal? — The position has narrowed sharply. The semaglutide and tirzepatide shortages were declared resolved in February 2025 and October 2024, and on April 30, 2026 the FDA proposed excluding both from the 503B bulks list. They currently appear on neither that list nor the shortage list.
Does Luvo offer real Ozempic or Zepbound? — Its weight-loss page lists brand Ozempic® and Zepbound® alongside compounded options. Confirm which you will receive before paying.
Does GLP-1 microdosing work? — There is no established clinical evidence base for it as a defined therapy. Approved products have studied dose-escalation schedules; deliberate sub-therapeutic dosing is not among them.
Who should not take a GLP-1? — Anyone with a personal or family history of medullary thyroid carcinoma or MEN 2, anyone pregnant or trying to conceive, and anyone with pancreatitis, gallbladder disease, gastroparesis or diabetic retinopathy without specific medical assessment first.
Are NAD+ and sermorelin proven? — The anti-ageing benefits they are marketed on have limited clinical evidence. Treat them as experimental rather than established.

The Bottom Line

Verdict: 5.0/10—a competently disclosed new platform asking for a year in advance, at the worst possible moment to prepay for compounded GLP-1s. Luvo does several things better than bigger competitors: it publishes real terms and a refund policy, it says outright that compounded medications are not FDA-approved, it does not take your money before a clinician has reviewed your case, and it offers brand Ozempic® and Zepbound® alongside compounded options. But its headline prices are weekly numbers attached to annual billing—$2,340 for weight loss, $1,300 for longevity—and its prorated refunds are calculated at the undiscounted monthly rate, so the annual saving only materialises if you finish the year. The brand is about two weeks old with no independent record, and it will not tell you which states it serves, who prescribes, or which pharmacy fills your script. Meanwhile the compounded pathway underpinning much of its weight-loss catalogue has lost its legal footing: both shortages are resolved and the FDA proposed on April 30, 2026 to exclude semaglutide and tirzepatide from the 503B bulks list. If you want what Luvo sells, ask for the brand pathway, ask for a monthly option, and get your state, prescriber and pharmacy confirmed in writing first. This review is informational only and not medical advice; GLP-1 medications have real contraindications, and you should consult a licensed clinician before starting or changing treatment. Prices and terms checked July 29, 2026 and subject to change.

Sources & References

Luvo Health — Official Site
Luvo Health — longevity and weight-loss service pages, FAQ, and cancellation and refund policy (checked July 29, 2026)
FDA — "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List" (April 30, 2026)
Federal Register — List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B (May 1, 2026)
FDA — drug shortage resolutions: tirzepatide (October 2024) and semaglutide (February 2025)
FDA — prescribing information and boxed warning for GLP-1 receptor agonists (medullary thyroid carcinoma, MEN 2)